INOVIQ Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

INOVIQ wird ein Gewinn- und Umsatzwachstum von 17.3% bzw. 84.3% pro Jahr prognostiziert, während der Gewinn pro Aktie um 27.1% pro Jahr wachsen soll.

Wichtige Informationen

17.3%

Wachstumsrate der Gewinne

27.1%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	19.6%
Wachstumsrate der Einnahmen	84.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	03 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

We Think INOVIQ (ASX:IIQ) Can Afford To Drive Business Growth

Apr 22

A Look At The Intrinsic Value Of INOVIQ Ltd (ASX:IIQ)

Mar 01

We Think Shareholders May Want To Consider A Review Of INOVIQ Ltd's (ASX:IIQ) CEO Compensation Package

Nov 22

Don't Ignore The Fact That This Insider Just Sold Some Shares In BARD1 Life Sciences Limited (ASX:BD1)

Mar 02

BARD1 Life Sciences (ASX:BD1) Is In A Good Position To Deliver On Growth Plans

Dec 28

Gewinn- und Umsatzwachstumsprognosen

ASX:IIQ - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (AUD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2026	8	-4	-3	-3	1
6/30/2025	2	-8	-7	-7	1
6/30/2024	1	-9	-8	-8	1
12/31/2023	2	-7	-6	-5	N/A
9/30/2023	2	-8	-6	-6	N/A
6/30/2023	2	-9	-7	-7	N/A
3/31/2023	2	-15	-7	-6	N/A
12/31/2022	2	-21	-6	-6	N/A
9/30/2022	2	-20	-6	-6	N/A
6/30/2022	2	-18	-7	-6	N/A
3/31/2022	2	-14	-6	-6	N/A
12/31/2021	1	-11	-6	-5	N/A
9/30/2021	1	-11	-6	-5	N/A
6/30/2021	1	-11	-6	-5	N/A
3/31/2021	1	-8	-6	-5	N/A
12/31/2020	1	-5	-5	-5	N/A
9/30/2020	1	-4	-4	-4	N/A
6/30/2020	1	-3	-3	-3	N/A
3/31/2020	1	-3	-2	-2	N/A
12/31/2019	0	-2	-2	-2	N/A
9/30/2019	1	-2	-2	-2	N/A
6/30/2019	1	-2	-2	-2	N/A
3/31/2019	0	-2	-2	-2	N/A
12/31/2018	0	-2	-2	-2	N/A
9/30/2018	0	-2	-2	-2	N/A
6/30/2018	0	-2	-2	-2	N/A
3/31/2018	0	-2	-2	-2	N/A
12/31/2017	0	-2	-2	-2	N/A
9/30/2017	0	-2	N/A	-2	N/A
6/30/2017	0	-3	N/A	-2	N/A
6/30/2016	N/A	-6	N/A	0	N/A
12/31/2015	N/A	0	N/A	0	N/A
12/31/2014	N/A	0	N/A	0	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IIQ wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: IIQ wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: IIQ wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: IIQDie Einnahmen des Unternehmens (84.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Australian (5.4% pro Jahr).

Hohe Wachstumseinnahmen: IIQDie Einnahmen des Unternehmens (84.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von IIQ in 3 Jahren voraussichtlich hoch sein wird

INOVIQ Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

INOVIQ Ltd has filed a Follow-on Equity Offering in the amount of AUD 2 million.

New minor risk - Share price stability

We Think INOVIQ (ASX:IIQ) Can Afford To Drive Business Growth

A Look At The Intrinsic Value Of INOVIQ Ltd (ASX:IIQ)

We Think Shareholders May Want To Consider A Review Of INOVIQ Ltd's (ASX:IIQ) CEO Compensation Package

INOVIQ Ltd, Annual General Meeting, Nov 28, 2023

Full year 2023 earnings released: AU$0.097 loss per share (vs AU$0.20 loss in FY 2022)

Insufficient new directors

Inoviq Limited Announces Clinical Validation Study for Subb2m/Ca15-3 Breast Cancer Test

New minor risk - Share price stability

Companies Like INOVIQ (ASX:IIQ) Are In A Position To Invest In Growth

First half 2023 earnings released: AU$6.70 loss per share (vs AU$0.031 loss in 1H 2022)

Companies Like INOVIQ (ASX:IIQ) Are In A Position To Invest In Growth

INOVIQ Limited Announces Positive Results for SubB2M Breast Cancer Test

INOVIQ Ltd Announces Resignation of Professor Allan Cripps AO as Director

INOVIQ Limited Announces Company Secretary Changes

INOVIQ Ltd, Annual General Meeting, Nov 28, 2022

INOVIQ (ASX:IIQ) Is In A Good Position To Deliver On Growth Plans

Full year 2022 earnings released: AU$0.072 loss per share (vs AU$0.14 loss in FY 2021)

High number of new directors

INOVIQ Limited Announces Positive SubB2M IHC Results for Melanoma

We're Hopeful That INOVIQ (ASX:IIQ) Will Use Its Cash Wisely

High number of new and inexperienced directors

INOVIQ Ltd Ordinary Shares to Be Deleted from Other OTC

INOVIQ Ltd Ordinary Shares to Be Deleted from Other OTC

Inoviq Limited Announces Update on Legal Proceedings and Bard1 Autoantibody Program

First half 2022 earnings: Revenues and EPS in line with analyst expectations

We're Keeping An Eye On INOVIQ's (ASX:IIQ) Cash Burn Rate

Full year 2021 earnings released: AU$0.14 loss per share (vs AU$0.072 loss in FY 2020)

Chief Scientific Officer Peter French has left the company

Chief Scientific Officer Peter French has left the company

BARD1 Life Sciences Limited Announces That Previously Reported Study Results for A Potential Bard1 Autoantibody Test for Early Detection of Ovarian Cancer in the International Peer-Reviewed Journal Genes

BARD1 Life Sciences Limited Announces SubB2M Breast Cancer Test Manuscript Submitted

Bard1 Life Sciences Limited Announces the Results of A Preliminary Study Which Demonstrates the Feasibility of Using Subb2m in an Ihc Application for Breast Cancer Tissue

BARD1 Life Sciences Limited Launches Its RUO EXO-NET Product

BARD1 Life Sciences Limited Presents BARD1 EXO-NET Exosome Data at ISEV2021 Conference

BARD1 Life Sciences Limited Announces Positive Results from the BARD1 autoantibody assay

BARD1 Life Sciences Limited Announces Positive Results Evaluation of EXO-NET in Pancreatic Cancer

BARD1 Life Sciences Limited Receives the Initial Purchase Order for AUD 80,000 from Mirax for hTERT

Bard1 Life Sciences Limited Gains Class II In-Vitro Diagnostic Medical Device Registration from South Korea's Ministry of Food and Drug Safety for the hTERT Test

Are Insiders Selling BARD1 Life Sciences Limited (ASX:BD1) Stock?

Don't Ignore The Fact That This Insider Just Sold Some Shares In BARD1 Life Sciences Limited (ASX:BD1)

Insider recently sold AU$8.2m worth of stock

BARD1 Life Sciences Limited Releases SUBB2M BREAST CANCER TEST DATA

Bard1 Life Sciences Limited Announces Outstanding SubB2M Ovarian Cancer Test Data

New 90-day low: AU$0.57

Dr. Irmgard Irminger-Finger Steps Down from Board of BARD1 Life Sciences Limited

New 90-day low: AU$0.61

BARD1 Life Sciences (ASX:BD1) Is In A Good Position To Deliver On Growth Plans

New 90-day low: AU$0.66

New 90-day low: AU$0.66

BARD1 Life Sciences Limited Announces Resignation of Helen Fisher as Non-executive Director

BARD1 Life Sciences Limited Gains New High-Volume Customer for Its hTERT test

BARD1 Life Sciences Limited Announces the Successful Evaluation of the BARD1 kit

BARD1 Life Sciences Limited Auditor Raises 'Going Concern' Doubt

Earnings released

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken